Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

donor TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated natural killer cells

A preparation of donor-derived, haploidentical, cytokine-activated natural killer (NK) cells enriched with mononuclear cells from haploidentical donor that have been depleted of T-cell receptor (TCR) alpha and beta (TCRa/b+) as well as CD19-positive (CD19+) cells, that may potentially be used for immune reconstitution purposes. Upon administration, the donor TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated NK cells may enhance immune reconstitution. The depletion of alpha/beta T cells, which are implicated in the adaptive immune response that mediates graft-versus-host disease (GvHD), may promote rapid and sustained engraftment, immune reconstitution, and may prevent or reduce the development of GvHD. The depletion of CD19+ B cells may reduce the risk of Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorders.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated NK cells
donor TCR alpha/beta/CD19-depleted mononuclear cell-enriched activated NK cells
TCR alphabeta/CD19-depleted DEA-NK cells
TCR alphabeta/CD19-depleted donor enriched activated natural killer cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search